UK – OOO Abbott v. Design & Display

Posted: November 22nd, 2017

OOO Abbott and another v Design & Display Limited and another, Intellectual Property Enterprise Court, UK, 22 November 2017 The UK Intellectual Property Enterprise Court considered issues arising relating to a determination of an account of profits following an earlier finding that Design & Display had infringed Abbott’s patent for slatted display panels. The Court […]


EPLAW – Update: registration EPLAW congress 24 November 2017 now closed

Posted: November 20th, 2017

Registration for the EPLAW congress on 24 November has now closed as the maximum number of participants has been reached. The final programme can be seen here. The EPLAW Board looks forward to welcoming all participants in Brussels!  


NL – Basic Holdings v. Ruby Decor

Posted: November 17th, 2017

Basic Holdings ULC v. Ruby Decor B.V. and Nijhof Zelfbouw Baarn B.V., Judge in interlocutory proceedings of the District Court in The Hague, 14 November 2017, Case No. ECLI:NL:RBDHA:2017:13109 Interlocutory proceedings. Infringement of patent on artificial fireplaces. Urgent interest, despite cease and desist declaration since the declaration does not cover all (cross border) measures and […]


NL – MSD v. Teva / Supreme Court – indirect infringement of Swiss type claims

Posted: November 14th, 2017

Merck Sharp & Dohme Corp. v. Teva Pharma B.V. and Pharmachemie B.V., Supreme Court of The Netherlands, The Hague, 3 November 2017, Case no ECLI:NL:HR:2017:2807 The Supreme Court holds that indirect infringement of a Swiss type claim is possible. A Swiss-type claim is in the form of a purpose bound method claim. If such a […]


FR – Applying statutes of limitations to patent revocations in France

Posted: November 9th, 2017

Applying statutes of limitations to patent revocations in France: Running solves nothing: you have to start moving at the right moment… but when? by Pauline Debré and Jean-François Merdrignac, Linklaters Paris Equity aids the vigilant, not the ones who sleep over their rights (iura vigilantibus, non dormientibus prosunt). This is also true for claimants in […]


UK – Actavis v. ICOS / Appeal

Posted: November 8th, 2017

Actavis Group PTC EHF & Others v (1) ICOS Corporation (2) Eli Lilly & Company The UK Court of Appeal has recently handed down its decision in Actavis v ICOS. Lewison, Kitchen and Floyd LLJ held that ICOS’s patent EP (UK) 1,173,181 (the “Patent”) was invalid for obviousness overturning the first instance decision of Birss […]


News – Unitary Patent Package Conference 2018

Posted: November 7th, 2017

On 8 and 9 February 2018 Euroforum will host the fifth edition of the Unitary Patent Package Conference in The Hague, The Netherlands Keynote speakers include Margot Fröhlinger (EPO), Kevin Mooney (Simmons & Simmons), and Marie Courboulay (Paris Court of Appeal). For more information and registration, please visit the conference website here.


UK – Mylan & Ors. v. Yeda

Posted: November 7th, 2017

Generics (UK) Limited trading as Mylan & Ors. v Yeda Research and Development Company Limited & Ors, High Court, London, UK, 26 October 2017, Neutral Citation Number: [2017] EWHC 2692 (Pat) This case was brought by the Claimants (Mylan and Synthon) seeking revocation of EP (UK) 2,949,335 (“EP’335”), a patent owned by Yeda and exclusively […]


NL – Sandoz v. Astrazeneca / Appeal

Posted: November 2nd, 2017

Sandoz B.V. v. Astrazeneca AB, Court of Appeal The Hague, The Netherlands, 31 October 2017, Case No. 200.200.332/01, with thanks to Willem Hoyng and Theo Blomme, HOYNG ROKH MONEGIER, for submitting the case including an English and German translation thereof Astrazeneca markets FASLODEX which is used for the treatment of oestrogen hormone dependent breast cancers. […]


CH – Eli Lilly v. Actavis / Swiss Federal Supreme Court (Pemetrexed)

Posted: November 1st, 2017

On 20 October 2017, the Swiss Federal Supreme Court handed down its decision in Eli Lilly vs. Actavis re infringement of Eli Lilly’s patent EP 1 313 508 regarding the use of the anti-cancer drug, pemetrexed in combination with a vitamin B12 to alleviate the harmful side-effects of the drug. In its decision, the Court […]